Bed Rest, Alternate Daily Fasting and Incretin Effect

NCT ID: NCT02134860

Last Updated: 2014-09-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bed rest produces insulin resistance in healthy volunteers. In this study the investigators aim to investigate the effect of 8 days bed rest on the incretin effect and how alternate daily fasting affects cognitive function and the insulin resistance produced by bed rest.

The subjects will be randomized to either 3 meals a day (isocaloric diet), alternate daily fasting or one meal/day every second day (25% of daily calorie need) and four meals/day every second (175% of daily calorie need).

The investigators hypothesize:

1. Bed rest reduces the incretin effect
2. Alternate daily fasting improves the cognitive function (memory and concentration) compared to isocaloric diet
3. Alternate daily fasting reduces insulin resistance produced by bed rest compared to isocaloric diet

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All subjects will undergo 8 days of bedrest. Outcome measures will be performed before, under and immediately after the bed rest period.

The individual study period will be 10 days in total.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome Type 2 Diabetes Critical Illness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Isocaloric diet

3 daily meals

Group Type ACTIVE_COMPARATOR

Bed rest

Intervention Type OTHER

8 days of full bed rest

OGTT

Intervention Type OTHER

Oral glucose tolerance test with 75 g of glucose before and after bed rest

IVGTT

Intervention Type OTHER

Intravenous glucose tolerance test mimicking the glucose profile from the corresponding OGTT

Cognitive testing

Intervention Type OTHER

Daily testing of memory and concentration using standardized tests

Muscle and fat biopsies

Intervention Type OTHER

Biopsies will be obtained before and after bed rest

Dual-energy X-ray Absorptiometry (DXA) scan

Intervention Type OTHER

DXA scan to evaluate fat and muscle distribution before and after bed rest

MRI

Intervention Type OTHER

Functional MRI to evaluate cognitive function and abdominal MRI to evaluate visceral fat before and after bed rest

Alternate daily fasting

One meal (25% of caloric need) every second day and four meals (175% of caloric need) every second day

Group Type ACTIVE_COMPARATOR

Bed rest

Intervention Type OTHER

8 days of full bed rest

OGTT

Intervention Type OTHER

Oral glucose tolerance test with 75 g of glucose before and after bed rest

IVGTT

Intervention Type OTHER

Intravenous glucose tolerance test mimicking the glucose profile from the corresponding OGTT

Cognitive testing

Intervention Type OTHER

Daily testing of memory and concentration using standardized tests

Muscle and fat biopsies

Intervention Type OTHER

Biopsies will be obtained before and after bed rest

Dual-energy X-ray Absorptiometry (DXA) scan

Intervention Type OTHER

DXA scan to evaluate fat and muscle distribution before and after bed rest

MRI

Intervention Type OTHER

Functional MRI to evaluate cognitive function and abdominal MRI to evaluate visceral fat before and after bed rest

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bed rest

8 days of full bed rest

Intervention Type OTHER

OGTT

Oral glucose tolerance test with 75 g of glucose before and after bed rest

Intervention Type OTHER

IVGTT

Intravenous glucose tolerance test mimicking the glucose profile from the corresponding OGTT

Intervention Type OTHER

Cognitive testing

Daily testing of memory and concentration using standardized tests

Intervention Type OTHER

Muscle and fat biopsies

Biopsies will be obtained before and after bed rest

Intervention Type OTHER

Dual-energy X-ray Absorptiometry (DXA) scan

DXA scan to evaluate fat and muscle distribution before and after bed rest

Intervention Type OTHER

MRI

Functional MRI to evaluate cognitive function and abdominal MRI to evaluate visceral fat before and after bed rest

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI\<25kg/m2
* VO2 max normal for age

Exclusion Criteria

* Tobacco smoking
* Alcohol ingestion \> 14 units per week
* Diabetes in nearby relatives
* Resection of the small intestine
* History of gastric bypass surgery
* Risk of deep venous thrombosis
* Female
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rigshospitalet, Denmark

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Anders Rasmussen Rinnov

MD, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nina Majlund Harder-Lauridsen, MD

Role: PRINCIPAL_INVESTIGATOR

Rigshospitalet, 7641

Signe Tellerup Nielsen, MD

Role: PRINCIPAL_INVESTIGATOR

Rigshospitalet, 7641

Rikke Krogh-Madsen, MD. PhD

Role: PRINCIPAL_INVESTIGATOR

Rigshospitalet, 7641

Bente Klarlund Pedersen, Professor

Role: STUDY_DIRECTOR

Rigshospitalet, 7641

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rigshospitalet

Copenhagen, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

References

Explore related publications, articles, or registry entries linked to this study.

Allaf M, Elghazaly H, Mohamed OG, Fareen MFK, Zaman S, Salmasi AM, Tsilidis K, Dehghan A. Intermittent fasting for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2021 Jan 29;1(1):CD013496. doi: 10.1002/14651858.CD013496.pub2.

Reference Type DERIVED
PMID: 33512717 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H-6-2014-017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Role of Metformin on Muscle Health of Older Adults
NCT03107884 ACTIVE_NOT_RECRUITING EARLY_PHASE1
The Fasting II Study
NCT01792986 COMPLETED NA